Race Oncology Ltd (ASX: RAC) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Race Oncology Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $138.61 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 163.07 million
Earnings per share -0.067
Dividend per share N/A
Year To Date Return -57.46%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Race Oncology Ltd (ASX: RAC)
    Latest News

    a man raises his fists to the air in joyous celebration while learning some exciting good news via his computer screen in an office setting.
    Share Gainers

    Why Lake Resources, Pro Medicus, Race Oncology, and Universal Store shares are rising today

    Let's take a closer look.

    Read more »

    medical asx share price represented by doctor giving thumbs up
    Healthcare Shares

    This ASX All Ords biotech share is on a 16% tear today

    What's getting investors excited about this biotech?

    Read more »

    A woman jumps for joy with a rocket drawn on the wall behind her.
    Healthcare Shares

    Guess which ASX All Ords share is soaring 12% on a 'key step'

    A positive update is getting investors very excited. What did the company announce?

    Read more »

    In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
    Healthcare Shares

    2 ASX healthcare shares racing higher on positive updates

    These healthcare shares are avoiding the market weakness on Wednesday.

    Read more »

    Rising share price chart.
    Share Gainers

    Why Allkem, IGO, Northern Star, and Race Oncology shares are racing higher

    These ASX shares are ending the week strongly.

    Read more »

    a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Share Gainers

    Why Aeris Resources, Evolution, Li-S Energy, and Race Oncology shares are charging higher

    These ASX shares are having a strong session on Tuesday.

    Read more »

    Four people on the beach leap high into the air.
    Share Gainers

    4 ASX All Ords shares smashing the market on big news

    Guess which All Ordinaries stock is soaring over 20% today.

    Read more »

    A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
    Share Fallers

    Why Block, Mincor, Race Oncology, and Weebit Nano shares are sinking today

    Investors have been selling these ASX shares on Friday.

    Read more »

    A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
    Share Fallers

    Why is ASX All Ords healthcare share Race Oncology plummeting 10% today?

    Its got something to do with the company's chief scientific officer and director.

    Read more »

    A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
    Share Gainers

    Why Neuren, Northern Star, Race Oncology, and Westgold shares are storming higher

    These ASX shares are starting the week in a positive fashion.

    Read more »

    A woman is excited as she reads the latest rumour on her phone.
    Share Market News

    4 ASX All Ords shares insiders have been buying up in January

    These insiders are putting money where their mouths are.

    Read more »

    A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
    Share Market News

    This ASX All Ords director has bought 25,000 of his company's shares in a week

    This director made a big investment last week.

    Read more »

    Frequently Asked Questions

    No, Race Oncology does not pay dividends at this time.

    Sydney-headquartered Race Oncology Ltd listed on the ASX on 13 July 2016.

    RAC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Race Oncology Ltd

    Race Oncology Ltd (ASX: RAC) is a clinical-stage global biotechnology company focused on cancer care.

    Race’s lead asset, bisantrene, is a small-molecule anthracene chemotherapeutic. It has demonstrated anti-cancer and cardio-protection effects in 46 clinical trials and around 70 peer-reviewed publications.

    The company is now taking its next-generation bisantrene to new fields of cancer treatment. It is initially focusing on two areas of unmet need: metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML).

    As part of its business strategy and clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway. This follows independent research describing bisantrene as the most potent inhibitor of fat mass and obesity-associated protein (FTO). Dysregulation of RNA (or the over-expression of FTO) has been shown to be a driver of a diverse range of cancers. Race and its partners are now in pre-clinical studies to explore the synergies and impact of bisantrene on FTO regulation.

    RAC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    01 Dec 2023 $0.85 $-0.01 -1.17% 84,183 $0.84 $0.85 $0.81
    30 Nov 2023 $0.86 $-0.06 -6.59% 252,304 $0.88 $0.90 $0.81
    29 Nov 2023 $0.91 $0.04 4.62% 108,562 $0.85 $0.91 $0.85
    28 Nov 2023 $0.87 $-0.03 -3.35% 147,314 $0.90 $0.90 $0.83
    27 Nov 2023 $0.90 $-0.02 -2.18% 108,421 $0.92 $0.92 $0.86
    24 Nov 2023 $0.92 $0.04 4.57% 410,485 $0.93 $0.93 $0.84
    23 Nov 2023 $0.88 $0.01 1.15% 368,599 $0.90 $0.95 $0.82
    22 Nov 2023 $0.87 $-0.04 -4.40% 1,050,985 $0.95 $1.00 $0.87
    21 Nov 2023 $0.91 $0.00 0.00% 15,768 $0.93 $0.94 $0.91
    20 Nov 2023 $0.91 $-0.03 -3.18% 24,350 $0.94 $0.94 $0.88
    17 Nov 2023 $0.94 $0.01 1.07% 62,900 $0.93 $0.94 $0.87
    16 Nov 2023 $0.93 $0.01 1.08% 19,307 $0.92 $0.93 $0.90
    15 Nov 2023 $0.92 $0.02 2.21% 109,345 $0.91 $0.95 $0.91
    14 Nov 2023 $0.90 $-0.02 -2.16% 91,165 $0.92 $0.93 $0.89
    13 Nov 2023 $0.92 $0.04 4.52% 131,690 $0.91 $0.92 $0.84
    10 Nov 2023 $0.89 $-0.03 -3.26% 165,701 $0.92 $0.93 $0.85
    09 Nov 2023 $0.92 $-0.08 -8.00% 313,087 $1.03 $1.03 $0.92
    08 Nov 2023 $1.00 $0.03 3.10% 617,859 $0.97 $1.07 $0.95
    07 Nov 2023 $0.97 $0.10 11.48% 821,429 $0.97 $1.01 $0.93

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    03 Mar 2023 Mary Harney Issued 110,392 $250,589
    Issue of options.
    03 Mar 2023 Daniel Sharp Issued 110,392 $250,589
    Issue of options.
    03 Mar 2023 Damian Clarke Bruce Issued 755,671 $1,715,373
    Issue of options.
    07 Feb 2023 Daniel Tillett Buy 6,793 $13,044
    On-market trade.
    13 Jan 2023 Daniel Tillett Buy 25,550 $50,223
    On-market trade. There is reporting error in the announcement for value, hence value has been updated according to price history. Considering 1.9656 per share value.
    20 Dec 2022 Daniel Tillett Buy 46,737 $99,198
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Phillip(Phil) R Lynch Non-Executive Director Feb 2023
    Mr Lynch has a career spanning more than 30 years in the Asia Pacific region with Johnson & Johnson. He is an experienced executive and board director, with a background across corporate development, strategy, financial performance, marketing and governance.
    Ms Mary Harney Non-Executive Director Feb 2021
    Ms Harney is the Director of specialist consulting firm Mary Harney Advisory providing leadership, governance and strategic advice across innovation industries such as health, biotech and agriculture. She currently also serves as Chairman of private Australian biotech Oncology One Pty Ltd, a cancer drug discovery company.
    Dr Peter (Pete) Smith Executive Director Jun 2023
    Dr Smith has over 30 years of experience in the pharmaceutical and biotech industry, in therapeutics, especially oncology. He has been involved in projects at all stages from concept to phase III clinical studies. He is currently CEO of private biotechnology company Myrio Therapeutics. Before joining Myrio, he was CEO of publicly listed Australian companies Alchemia and AMRAD. Prior to moving to Australia, Peter co-founded and was CFO of Onyvax Ltd, a cancer immunotherapy company based in London. At the start of his career, he was a top-rated Pharmaceuticals Analyst with UBS and HSBC, being involved in numerous transactions including LSE/NASDAQ IPOs, fundraisings, and M&A. His undergraduate degree and PhD are from the University of Cambridge. In addition to serving as a Director of Race Oncology, he is also currently a Director of Myrio Therapeutics, MycRx Inc., Hula Therapeutics Inc. and Amala Therapeutics.
    Mr Peter Webse Company Secretary Aug 2016
    Peter Webse Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Dr Daniel Tillett 14,014,370 8.59%
    Mr Phillip Richard Perry 6,047,694 3.71%
    Mr Mark Phillip Juan 5,652,312 3.47%
    Biosynergy Partners Pty Ltd 5,102,194 3.13%
    The Trust Company (Australia) Limited <MOF A/C> 4,450,468 2.73%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 2,648,807 1.62%
    Dr Daniel Tillett (ii) 2,307,925 1.42%
    Craganorig Holdings LLC 2,000,000 1.23%
    Marinella Messina 1,757,377 1.08%
    Mr Phillip Richard Perry & Mrs Tetyana Perry <Doneska Super Fund A/C> 1,600,000 0.98%
    Mr Anthony James Robinson <The Peeko Family No 86 A/C> 1,579,250 0.97%
    Mr Kimberley Ross Gartrell & Mrs Jennifer Margaret Gartrell <K&J Gartrell Super Fund A/C> 1,350,000 0.83%
    Kudoss Investments Pty Ltd <Aitken Global Family A/C> 1,153,034 0.71%
    Mr Kenneth Barry Ridley & Mrs Catherine Mary Ridley <Ridley Retirement Fund A/C> 1,080,000 0.66%
    Mr Sandor Helby 1,060,000 0.65%
    Mr Alan Giles Sauran 1,031,256 0.63%
    Biosynergy Partners Pty Ltd (ii) 1,000,000 0.61%
    Citicorp Nominees Pty Limited 856,443 0.53%
    Mr Van Quy Do 825,788 0.51%
    Mr Brian James Walker 777,777 0.48%